A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors
To evaluate safety and tolerability of PF-00299804 in Japanese patients with advanced malignant solid tumors at doses up to the clinically recommended phase 2 dose in non-Japanese studies.
Neoplasms
DRUG: PF-00299804
Overall safety: type, grade and frequency of all adverse events and laboratory abnormalities, End of study
To explore PD markers, End of study|To evaluate the plasma pharmacokinetics of PF-00299804 in Japanese patients following single and multiple dosing, End of study|To assess any clinical evidence of anti-tumor activity of PF-00299804 per RECIST, End of study
To evaluate safety and tolerability of PF-00299804 in Japanese patients with advanced malignant solid tumors at doses up to the clinically recommended phase 2 dose in non-Japanese studies.